| GTO ID | GTC1256 |
| Trial ID |
NCT00362180
|
| Disease |
Dyslipidemias
|
Familial Hypercholesterolemia
|
Lipid Metabolism Disorder
|
Genetic Disease
|
Hyperlipoproteinemia Type II
|
Metabolic Disease
|
| Altered gene | APOB |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | ISIS 301012|mipomersen sodium|Kynamro |
| Location approved | US, Mexico, Argentina, South Korea |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Apolipoprotein B(ApoB) Reduction by ISIS 301012 on Liver Triglyceride Content in Subjects With Varying Degrees of Hyperlipidemia |
| Year | 2006 |
| Country | Netherlands |
| Company sponsor | Kastle Therapeutics, LLC |
| Other ID(s) | 301012-CS10|2005-005783-90 |